NCT03355976 2026-04-02BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasBrown UniversityPhase 2 Active not recruiting46 enrolled
NCT02873962 2026-04-01A Phase II Study Of Nivolumab/ Bevacizumab/RucaparibDana-Farber Cancer InstitutePhase 2 Active not recruiting72 enrolled 16 charts
NCT03872947 2025-08-03A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsToray Industries, IncPhase 1 Active not recruiting138 enrolled